Your browser doesn't support javascript.
loading
Human iPS cell-derived mural cells as an in vitro model of hereditary cerebral small vessel disease.
Yamamoto, Yumi; Kojima, Katsutoshi; Taura, Daisuke; Sone, Masakatsu; Washida, Kazuo; Egawa, Naohiro; Kondo, Takayuki; Minakawa, Eiko N; Tsukita, Kayoko; Enami, Takako; Tomimoto, Hidekazu; Mizuno, Toshiki; Kalaria, Raj N; Inagaki, Nobuya; Takahashi, Ryosuke; Harada-Shiba, Mariko; Ihara, Masafumi; Inoue, Haruhisa.
Afiliación
  • Yamamoto Y; Research Fellow of Japan Society for the Promotion of Science, Tokyo, Japan.
  • Kojima K; Department of Molecular Innovation in Lipidemiology, National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibeshinmachi, Suita-shi, Osaka, 564-0018, Japan.
  • Taura D; Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Sone M; Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Washida K; Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. sonemasa@kuhp.kyoto-u.ac.jp.
  • Egawa N; Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita-shi, Osaka, 564-0018, Japan.
  • Kondo T; Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Minakawa EN; iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
  • Tsukita K; Department of Neurology, Kyoto University Graduate School of Medicine, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Enami T; Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Tomimoto H; iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
  • Mizuno T; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.
  • Kalaria RN; Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8502, Japan.
  • Inagaki N; Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Takahashi R; iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
  • Harada-Shiba M; Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Ihara M; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.
  • Inoue H; Department of Dementia Prevention and Therapeutics, Graduate School of Medicine, Mie University, 2-174 Edobashi Tsu, Mie, 514-8507, Japan.
Mol Brain ; 13(1): 38, 2020 03 19.
Article en En | MEDLINE | ID: mdl-32188464
ABSTRACT
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is one of the most common forms of hereditary cerebral small vessel diseases and is caused by mutations in NOTCH3. Our group has previously reported incorporation of NOTCH3 extracellular domain (N3ECD) in the CADASIL-specific granular osmiophilic materials and increase of PDGFRß immunoreactivity in CADASIL postmortem brains. Here, we aimed to establish an in vitro model of CADASIL, which can recapitulate those CADASIL phenotypes, using induced pluripotent stem cells (iPSCs). We have refined a differentiation protocol of endothelial cells to obtain mature mural cells (MCs) with their characteristic properties. iPSCs from three CADASIL patients with p.Arg182Cys, p.Arg141Cys and p.Cys106Arg mutations were differentiated into MCs and their functional and molecular profiles were compared. The differentiated CADASIL MCs recapitulated pathogenic changes reported previously increased PDGFRß and abnormal structure/distribution of filamentous actin network, as well as N3ECD/LTBP-1/HtrA1-immunopositive deposits. Migration rate of CADASIL MCs was enhanced but suppressed by knockdown of NOTCH3 or PDGFRB. CADASIL MCs showed altered reactivity to PDGF-BB. Patient-derived MCs can recapitulate CADASIL pathology and are therefore useful in understanding the pathogenesis and developing potential treatment strategies.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Enfermedades de los Pequeños Vasos Cerebrales / Modelos Biológicos Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Mol Brain Asunto de la revista: BIOLOGIA MOLECULAR / CEREBRO Año: 2020 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Enfermedades de los Pequeños Vasos Cerebrales / Modelos Biológicos Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Mol Brain Asunto de la revista: BIOLOGIA MOLECULAR / CEREBRO Año: 2020 Tipo del documento: Article